RobertStevenBuschMD

Endocrinology • Albany, NY

Diabetes, Lipid Metabolism, Thyroid

Assistant Clinical Professor, Endocrinology, Albany Medical College

Join to view full profile

Dr. Busch is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Busch's full profile

Already have an account?

Office
1365 Washington Ave
Ste 300
Albany, NY 12206
Phone+1 518-489-4704

Fax+1 518-489-0512

Education & Training

Albany Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1984
N Shore U1981
Zucker School of Medicine at Hofstra/NorthwellInternship, Internal Medicine, 1978 - 1979
Perelman School of Medicine at the University of PennsylvaniaClass of 1978

Certifications & Licensure

NY State Medical License 1979 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

Hudson Valley Magazine Castle Connolly, 2012-2013
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Fellow (FACE) American Association of Clinical Endocrinology

Clinical Trials

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus Start of enrollment: 2010 Jun 18
Completed
Phase 3
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) Start of enrollment: 2012 Jul 01
Completed
Phase 3
Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease Start of enrollment: 2013 Mar 18
Terminated
Phase 2

Publications & Presentations

PubMed

187 citations
Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
Bernard Zinman, Vaishali Bhosekar, Robert S. Busch, Ingrid Holst, Bernhard Ludvik
The Lancet. Diabetes & Endocrinology. 2019-05-01
7 citations
Large Between-Patient Variability in eGFR Decline Before Clinical Trial Enrollment and Impact on Atrasentan's Efficacy - A Post-Hoc Analysis From the SONAR Trial.
Simke W. Waijer, Sieta T. de Vries, Robert S. Busch, Di Xie, Ron T. Gansevoort
Journal of the American Society of Nephrology. 2021-08-20
6 citations
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.
Johannes F E Mann, Peter Rossing, George Bakris, Nicolas Belmar, Heidrun Bosch-Traberg
Nature Medicine. 2024-10-01

Press Mentions

Endocrinology Clinical Trials Program ThrivingMay 4th, 2022
50 Things Doctors Would Tell Their Own MothersAugust 9th, 2019
Diabetes Increases the Risk of Heart Failure More in Women Than in MenJuly 22nd, 2019
Join now to see all